17 active not recruiting. 17 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Active not recruiting 17 |
| Phase 2 | 4 | Active not recruiting 4 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation Ketofol, propofol (drug) - The Critically Ill Patient is Requiring Intubation, Septic Shock | Phase 3 | Active not recruiting | Helwan University | 70 | 2026-05-13 | 2026-10-15 |
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination 31-valent pneumococcal conjugate vaccine, PCV20 - Pneumococcal Vaccines | Phase 3 | Active not recruiting | Vaxcyte, Inc. | 752 | 2026-02-09 | 2026-06-30 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo - Pneumococcal Disease | Phase 3 | Active not recruiting | Vaxcyte, Inc. | 1390 | 2026-01-12 | 2026-11-02 |
| Study of VYD2311 for the Prevention of COVID-19 VYD2311-SD, VYD2311-MD, Placebo - COVID-19 | Phase 3 | Active not recruiting | Invivyd, Inc. | 1770 | 2026-01-08 | 2026-06-10 |
| A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women GBS-NN/NN2 vaccine - Streptococcus Agalactiae Infection, Neonatal Sepsis | Phase 2 / Phase 3 | Active not recruiting | Minervax ApS | 137 | 2025-03-07 | 2026-09-04 |
| Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers AdCLD-CoV19-1 OMI, Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) - COVID-19, Vaccines | Phase 3 | Active not recruiting | Cellid Co., Ltd. | 4000 | 2023-11-27 | 2024-11-15 |
| PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway Nirmatrelvir/ritonavir, Placebo - Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection | Phase 3 | Active not recruiting | Haukeland University Hospital | 2000 | 2023-05-12 | 2025-11-21 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia Azeliragon, Placebo - COVID-19 | Phase 2 / Phase 3 | Active not recruiting | The University of Texas Medical Branch, Galveston | 144 | 2023-05-04 | 2025-03-03 |
| COVID-19 Booster Study in Healthy Adults in Australia Bivalent Moderna, Novavax - COVID-19 | Phase 3 | Active not recruiting | Murdoch Childrens Research Institute | 496 | 2023-02-28 | 2026-01-02 |
| Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings Paxlovid, Antioxidant - COVID-19 | Phase 3 | Active not recruiting | Unity Health Toronto | 797 | 2023-01-16 | 2025-05-16 |
| Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19 Prednisolone, Losartan - COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle | Phase 3 | Active not recruiting | Valentina Puentmann | 279 | 2022-12-12 | 2025-12-09 |
| Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy Atorvastatin, Standard Care - Neurocognitive Impairment, Mild | Phase 3 | Active not recruiting | The George Institute | 190 | 2022-03-10 | 2025-04-10 |
| Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis Sirolimus - Pulmonary Fibrosis, COVID-19 Pneumonia | Phase 2 / Phase 3 | Active not recruiting | University of Chicago | 60 | 2021-07-09 | 2025-12-15 |
| The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines BCG (Bacillus Calmette-Guérin) vaccine, Placebo - COVID-19 | Phase 3 | Active not recruiting | Oswaldo Cruz Foundation | 556 | 2021-05-27 | 2025-08-08 |
| Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults Intramuscular injection, Intramuscular vaccine - SARS-CoV-2 Infection | Phase 2 / Phase 3 | Active not recruiting | Medicago | 30918 | 2020-11-19 | 2022-04-06 |
| SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival Isoflurane Inhalant Product, Sevoflurane inhalant product - Covid19, Hypoxic Respiratory Failure | Phase 3 | Active not recruiting | Sunnybrook Health Sciences Centre | 800 | 2020-06-15 | 2026-02-09 |
| The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients Cholecalciferol, Placebo - Critical Illness, Vitamin D Deficiency | Phase 3 | Active not recruiting | Medical University of Graz | 2400 | 2017-10-10 | 2026-10-09 |
COVID-19 (11) · Pneumococcal Infections (2) · Post-Acute COVID-19 Syndrome (2) · Acute Kidney Injury (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Critical Illness (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Lymphoma, Follicular (1) · Meningitis (1) · Microvascular Angina (1) · Myocarditis (1) · Neonatal Sepsis (1)
Lung Diseases (17) · Respiratory Tract Diseases (17) · Respiratory Tract Infections (17) · Infections (16) · Coronaviridae Infections (13) · Coronavirus Infections (13) · Nidovirales Infections (13) · Pneumonia, Viral (13) · RNA Virus Infections (13) · Virus Diseases (13) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (5) · Disease Attributes (3) · Bacterial Infections (2)
nirmatrelvir and ritonavir drug combination (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Antioxidants (1) · Atorvastatin (1) · BNT162 Vaccine (1) · Cholecalciferol (1) · FluBlok (1) · Injections, Intramuscular (1) · Losartan (1) · NVX-CoV2373 adjuvated lipid nanoparticle (1) · Pharmaceutical Preparations (1) · Prednisolone (1) · Propofol (1) · Sirolimus (1) · Standard of Care (1)
Vaxcyte, Inc. (2) · Cellid Co., Ltd. (1) · Haukeland University Hospital (1) · Helwan University (1) · Invivyd, Inc. (1) · Medicago (1) · Medical University of Graz (1) · Minervax ApS (1) · Murdoch Childrens Research Institute (1) · Oswaldo Cruz Foundation (1) · Sunnybrook Health Sciences Centre (1) · The George Institute (1) · The University of Texas Medical Branch, Galveston (1) · Unity Health Toronto (1) · University of Chicago (1)
United States (6) · Canada (3) · Australia (2) · Austria (2) · Brazil (2) · Germany (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Denmark (1) · Egypt (1) · Mexico (1) · Norway (1) · Philippines (1) · South Africa (1)
Ayodeji Adegunsoye, MD, MS (1) · Brian Ward, MD (1) · Craig Anderson, MD (1) · Eike Nagel, MD, PhD (1) · Haroldo J Matos, MD PhD (1) · Helena LC Santos, PhD (1) · Igor C Johansen, PhD (1) · Irineide A Antunes, MD (1) · Karin Amrein, MD, MSc (1) · Kezia KG Scopel, PhD (1) · Kim Mulholland, MD/Prof (1) · Lucas S. Blanton, MD (1) · Lucilaide O Santos, MD (1) · Marcelo U Ferreira, MD PhD (1) · Nina Langeland, MD, PhD (1)
PMID 31722941, PMID 33757717, PMID 35507508, PMID 40228860, PMID 40754325, PMID 41083292, PMID 41199272, PMID 41756075, PMID 41985658, PMID 42019019, PMID 42462744, PMID 42533000, PMID 42872958